

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	LaColla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No:	11874-016-999 (CAM: 417451-999016) IDX 1017

AMENDMENT AFTER ALLOWANCE UNDER 37 C.F.R. § 1.312

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The following amendment supplements the amendment filed on January 8, 2009 in response to the Office Action of July 10, 2008. Submitted concurrently herewith is a Petition under 37 C.F. R. § 1.182, along with the petition fee set forth in 37 C.F.R. § 1.17(f).

Pursuant to 37 C.F.R. § 1.312, Applicants respectfully request entry of the following amendments and remarks without withdrawing the application from issue.

Pursuant to 37 C.F.R. § 1.71(g)(2), the processing fee set forth in 37 C.F.R. § 1.17(i) for the amendment to the specification will be paid via EFS Web.

Amendments to the Specification begin on page 2.

Remarks begin on page 3.